Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 17, 2002

View Archived Issues

BMOV enters phase II for treatment of severe burns in children

Potential for Ono-AE1-329 in the treatment of inflammatory bowel disease

Edrecolomab effective against bone marrow metastases of breast cancer

Further data on efficacy and safety of deferiprone in beta-thalassemia

RPR-109881A: pharmacokinetics in patients with advanced solid tumors

GLP-1 and its analogue LY-315902 inhibit intestinal motility and reduce plasma somatostatin

Recent studies support Pyridorin as a potentially important advance in diabetic nephropathy

Oralin compares favorably with s.c. insulin after a meal in type 1 and 2 diabetes

Pharmacokinetics/pharmacodynamics of inhaled insulin investigated in different patient populations

Aminoglycoside antibiotics identified by Wayne State U. researchers

Merck researchers present new NK1 antagonists for pain, emesis, etc.

Merck & Co. presents new thrombin inhibitors

NAALADase inhibitors synthesized and tested at Guilford

First regulatory filing for an HIV fusion inhibitor

New ileal bile acid transport inhibitors in the Sankyo pipeline

Sankyo patent covers new triazole antifungal agents

Inhibitors of IL-4 production with potential in asthma, allergy and other disorders

Synthetic secretin available for diagnosing pancreatic dysfunction and gastrinoma

Transdermal PTH-based product in development for osteoporosis

Selective NK1 antagonist derived from dual NK1/NK2 antagonist at AstraZeneca

Lundbeck and Abbott to copromote Lexapro in Latin America

Phase II Ceplene triple-drug trial cleared to continue

Phase II IND cleared for NCX-701

MLN-02 fails to meet primary endpoint in phase II Crohn's disease trial

Patient enrollment completed in phase II MC-1 trial

Wyeth advances NSP-989 into the clinic

Diachrome evaluated for ability to improve blood glucose control in type 2 diabetes patients

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 9, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 9, 2026.
ADCs’ breakout 2025 and their still-unfinished potential
BioWorld Science
Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...
Development and characterization of anti-CD19 in vivo CAR T therapy
BioWorld Science
Shenzhen Grit Biotechnology Co. Ltd. and Shanghai Vitalgen Biopharma Co. Ltd. recently presented their work to develop and evaluate a novel anti-CD19 in vivo CAR...
Preclinical results of anti-ADAMTS13 antibody in acquired von Willebrand syndrome
BioWorld Science
The acquired von Willebrand syndrome (AVWS) is a rare bleeding disorder with laboratory findings similar to those of inherited von Willebrand disease. Researchers...